RxDoctor Payments Data

Steven Waggoner, MD

Gynecologic Oncology · Cleveland, OHNPI 1851322150

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gynecologic oncology clinicians in OH, where the typical reported total is $1,215.

$313in general payments, 2019–2025

Across 14 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopersurgical, Inc.$60
  • Novocure Inc.$39
  • Genmab U.S., Inc.$35
  • GSK$31
  • AbbVie$29
  • Baxter Healthcare$27
  • plus $92 from 5 others
$544,583in research payments, 2019–2025

Across 157 payments — averaging $3468.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Trillium Therapeutics USA, LLC$238K
  • Genentech, Inc.$144K
  • GSK$129K
  • Regeneron$22K
  • Pfizer$10K
  • Merck$2K

What the payments were for

  • Food & beverage$30297%
  • Education$113%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$313 in reported general payments places this provider in the 15th percentile of 62 gynecologic oncology providers in Ohio.

See all gynecologic oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$47,230
Medicare patients
115
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →